Table 28:
Proportion of Patients Achieving ≥ 50% Reduction in Number of Headache Days, nVNS vs. Control, Prevention, Migraine
| Author, year (study) | Participants, nVNS/control, n | % Achieving ≥ 50% response | Relative effect | P | |
|---|---|---|---|---|---|
| nVNS | Control | ||||
| Silberstein et al, 201656 (EVENT) | 30/29 | 10 | 0 | RR 6.77 (0.37-125.65)a | NS |
| Diener et al, 201957 (PREMIUM) | 165/167 | 28.5 | 25.6 | OR 1.16 (0.69-1.95)b | .57b |
Abbreviations: CI, confidence interval; NS, not significant; nVNS, noninvasive vagus nerve stimulation; OR, odds ratio; RR, relative risk.
a
Calculated in Cochrane RevMan.40
b
Adjusted for treatment group, centre, presence or absence of aura, and number of headache days at baseline.